Shanghai Bio-heart wins China NMPA approval for Bioheart biodegradable drug-eluting stent

PUBT · 3d ago
Shanghai Bio-heart wins China NMPA approval for Bioheart biodegradable drug-eluting stent
  • China’s NMPA cleared Shanghai Bio-heart’s Bioheart fully bioresorbable drug-eluting stent for coronary artery disease-related ischemic heart disease.
  • Approval dated June 29, 2026, covering use to improve coronary lumen diameter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bio-heart Biological Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300952), on August 26, 2026, and is solely responsible for the information contained therein.